Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

NCT ID: NCT07146217

Last Updated: 2025-08-28

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-31
• Study Completion Date: 2026-10-31

Brief Summary

This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to <4 years with anaerobic bacterial infection

Conditions

Bacterial Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Likmez® (metronidazole) Oral Suspension

Group Type: EXPERIMENTAL

Likmez® (metronidazole) Oral Suspension

Intervention Type: DRUG

Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL

Interventions

Likmez® (metronidazole) Oral Suspension

Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age between ≥ 12 months and < 4 years till the time of dosing in the study
• Sufficient venous access to permit cannulation for required blood sample collection.
• Ability to swallow oral liquids.
• Clinical diagnosis with suspected or culture-confirmed anaerobic bacterial infection with pathogens known to be sensitive to metronidazole and requiring treatment for any of the below mentioned infections:

1. Septicaemia and Bacteraemia

2. Intra-abdominal infections (including peritonitis, intra-abdominal abscess, and liver abscess)

3. Bone and joint infections (including osteomyelitis)

4. Lower respiratory tract infections (including pneumonia, empyema, and lung abscess)

• Patients with clinical diagnosis of polymicrobial infection who can be administered Likmez® with other antibacterial agents without clinically significant drug-drug interactions. Note: These patients will be allowed concomitant administration with other antibacterial drugs, not having an interaction with metronidazole (Refer APPENDIX B: List of Antibiotic Drugs Having Interaction with Metronidazole, for the list of antibiotic drugs having interaction with metronidazole). If co-administration of such medications cannot be avoided, PI should consider taking steps to minimize the risk of QT/QTc interval prolongation and torsade de pointes (TdP), such as electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP.
• Any of the above mentioned clinical conditions, which would allow them to initiate the treatment with IV or oral anti-bacterial drugs with activity against anaerobic bacteria (e.g., IV treatment such as a betalactam/beta-lactamase inhibitor or a cephalosporin plus metronidazole; or oral treatment such as amoxicillin, amoxicillin-clavulanate, or azithromycin) followed by treatment with i.e. Likmez® at 7.5 mg/kg, to complete the treatment course and are able to provide PK samples for the study.
• Parents/legal guardians of the patient have provided Written Informed Consent prior to initiation of any protocol-specific procedures.

Exclusion Criteria

• History of anaphylactic reaction to metronidazole or other nitroimidazole derivatives (e.g., tinidazole).
• Presence of clinically significant encephalopathy or peripheral neuropathy.
• Presence or history of clinically significant convulsive seizure disorders.
• Presence or history of any hematologic condition or blood dyscrasia which may result in leukopenia (even if leukocyte count is normal at screening).
• Abnormal laboratory results for the following analyses showing any of the following abnormal results:

1. Aspartate aminotransferase (AST), alanine transaminase (ALT)>2 X the upper limit of the reference range

2. WBC count <3.0 X 109 /L

3. Total bilirubin ≥20 μmol/L (1.17 mg/dL); except in patients with isolated elevation of indirect bilirubin relating to Gilbert syndrome

4. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 using the Bedside Schwartz methods for estimation (eGFR = 41.3 x height/serum creatinine (Scr), where height is in meters and Scr in mg/dL)

5. Hemoglobin <8 g/dL

6. Platelets <100,000/μL

• History or presence of any clinically significant disease or disorder that, in the opinion of the investigator, would put the patient at risk or would potentially influence the results of the study (e.g. evidence of gastrointestinal, hepatic, or renal disease that could affect absorption, distribution, metabolism, or excretion of the orally administered study drug).
• Patients with a history of hereditary fructose intolerance (HFI) or rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
• Patients with a known sensitivity to glucose (e.g. patients with a diagnosis of diabetes or patients taking a ketogenic diet).
• Patients with a history of Severe cutaneous adverse reactions (SCARs), including Stevens Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).
• Patients who have used disulfiram within the last two weeks prior to enrollment in study.
• Patients who have consumed products containing propylene glycol within a week prior to enrollment in study and who wish to continue products containing propylene glycol during the study and for at least three days after the end of treatment period.
• Patients with known status of Cockayne syndrome.
• Patients with treatment with any another drug that is known to have pharmacokinetic interaction [For example: barbiturates such as phenytoin or phenobarbital] with metronidazole, within 30 days prior to enrollment or within 5.5 half-lives of the drug, (whichever is longer), until the end of study.
• Previous exposure to metronidazole within 30 days of enrollment.
• Patients with a known history of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV), and latent tuberculosis (TB) infections.
• Previous participation in this study.

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CBCC Global Research

NETWORK

Sponsor Role: collaborator

Saptalis Pharmaceuticals LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Polireddy Dondeti, PhD

Role: STUDY_CHAIR

President & CEO

Locations

Bioresearch Partner

Miami, Florida, United States

Empire Medical Clinical Trials

Miami, Florida, United States

Aavon Clinical Trials

Richmond, Texas, United States

Countries

United States

Central Contacts

Santhy John

Role: CONTACT

santhy.john@saptalis.com

631-231-2751 ext. 111

Veera Somasani

Role: CONTACT

veera.somasani@saptalis.com

631-231-2751 ext. 111

Facility Contacts

Tania Franco

Role: primary

tfranco@bioresearchpartner.com

307-206-5889

Suzelle Costales

Role: backup

scostales@bioresearchpartner.com

Estrada Nailan

Role: primary

Nailan.e@empireclinicaltrials.com

(786) 667-1617

Yovanny Blanco

Role: backup

Yovannu.b@empireclinicaltrial.com

Zitiali Alanis

Role: primary

azitiali@aavonclinical.com

713-282-5600

Prashant Zanzane

Role: backup

zprashant@aavonclinical.com

Other Identifiers

ATI-1501-0X

Identifier Type: -

Identifier Source: org_study_id